WEXFORD, Pa., Sept. 5, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today issued a shareholder letter from its Chief Executive Officer Dave Mehalick. Dear Coeptis Therapeutics Shareholders, As summer comes to a close, I am pleased to share with you the latest updates and accomplishments at Coeptis Therapeutics. For the scientific a ...